News

2017

Flagship Pioneering and its portfolio companies make news because of their transformative approaches to solving global challenges. If you have needs beyond these resources, please contact press@flagshippioneering.com.

company

year

domain

FDA Grants Fast Track Designation to Visterra’s VIS410 for Treatment of Hospitalized Patients with Influenza A

Visterra 11.01.2017

Visterra Announces Research Collaboration, Exclusive License, and Option Agreement for Infectious Diseases with Vir Biotechnology

Visterra 10.18.2017

Visterra Awarded CARB-X Contract to Advance Development of VIS705

Visterra 03.30.2017

Visterra Doses First Patient in Phase 2a Trial for VIS410, its Monoclonal Antibody in Development for the Treatment of Hospitalized Patients with Influenza A

Visterra 01.11.2017

Loading